Rapporto sulle dimensioni del mercato delle lesioni polmonari acute e sull’analisi delle quote | Previsioni 2031

  • Report Code : TIPRE00015798
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 141
Buy Now

Si prevede che il mercato delle lesioni polmonari acute raggiungerà i 741,98 milioni di dollari entro il 2028 rispetto ai 539,61 milioni di dollari del 2021; si prevede che registrerà un CAGR del 4,7% dal 2021 al 2028.

La lesione polmonare acuta (ALI) è una condizione pericolosa per la vita in pazienti gravemente malsani. Nel disturbo da danno polmonare acuto, si verifica un'infiammazione acuta nel polmone, che porta alla rottura delle barriere endoteliali ed epiteliali polmonari. La membrana alveolo-capillare è composta dall'endotelio microvascolare, dall'interstizio e dall'epitelio alveolare. Il mercato delle lesioni polmonari acute viene diagnosticato clinicamente sulla base della comparsa di odema polmonare non cardiogeno e insufficienza respiratoria in un paziente critico. La sua incidenza è normale; è probabile che esista al di fuori del contesto di terapia intensiva e pertanto è una condizione rilevante per tutti i medici.

Il rapporto offre approfondimenti e analisi approfondite della lesione polmonare acuta mercato, sottolineando vari parametri come le tendenze del mercato, i progressi tecnologici, le dinamiche di mercato e l’analisi del panorama competitivo dei principali attori del mercato in tutto il mondo. Include anche l’impatto della pandemia COVID-19 sul mercato in tutte le regioni. La pandemia di COVID-19 ha sconvolto le condizioni socioeconomiche di vari paesi in tutto il mondo. Attualmente, gli Stati Uniti sono il paese più colpito al mondo a causa dell’epidemia di COVID-19 con il maggior numero di casi confermati e decessi, secondo le recenti statistiche dell’OMS. L’elevato numero di casi COVID ha avuto un impatto negativo sulle economie del Paese e della regione. Si è verificato un calo delle attività commerciali complessive e una crescita di varie industrie che operano nella regione.

Tuttavia, gli operatori del mercato delle lesioni polmonari acute stanno avviando studi clinici per sviluppare farmaci per trattare il danno polmonare acuto. Ad esempio, Chimerix, un’azienda biofarmaceutica, ha avviato uno studio clinico di Fase II/III nel giugno 2020 per valutare la sicurezza e l’efficacia del dociparstat sodico (DSTAT) in pazienti con danno polmonare acuto (ALI) dovuto a COVID-19. Inoltre, Altasciences è lieta di supportare ReAlta Life Sciences conducendo uno studio di Fase I per valutare RLS-0071 per il danno polmonare acuto (ALI) a seguito di infezioni virali come COVID-19, virus respiratorio sinciziale (RSV) e influenza. I problemi legati al COVID-19 hanno spinto la crescita del mercato delle lesioni polmonari acute nella regione.

In base alla regione, il mercato è segmentato in Nord America, Europa, Asia Pacifico, Medio Oriente e Asia. Africa e America meridionale e centrale.

Regioni redditizie per il mercato delle lesioni polmonari acute


Approfondimenti di mercato

L'aumento della prevalenza delle malattie respiratorie determina il mercato delle lesioni polmonari acute

L'elevata prevalenza delle patologie respiratorie è associata alla diminuzione delle dimensioni dei polmoni il lume delle vie aeree superiori nella popolazione che invecchia. I disturbi polmonari sono tra le condizioni mediche più comuni in tutto il mondo. Secondo i Centri per il controllo e la prevenzione delle malattie (CDC), le malattie polmonari come la broncopneumopatia cronica ostruttiva (BPCO) e il danno polmonare acuto (ALI) sono la terza causa di morte negli Stati Uniti. Le persone in tutto il mondo soffrono di vari tipi di malattie respiratorie. Il fumo, le infezioni e i fattori genetici sono tra i fattori comuni responsabili dei disturbi respiratori. Condizioni mediche come la BPCO, l'asma, la bronchite cronica, la fibrosi cistica e il cancro ai polmoni rappresentano un onere significativo per la salute pubblica.

I pazienti che soffrono di questi disturbi respiratori comunemente riscontrano difficoltà a respirare . L'insufficienza respiratoria associata a danno polmonare acuto o alla sindrome da distress respiratorio acuto (ARDS) è uno dei fattori che contribuiscono maggiormente alla mortalità postoperatoria.

Inoltre, il CDC, il La Food and Drug Administration (FDA) statunitense, i dipartimenti sanitari statali e locali e altri operatori sanitari e clinici continuano a monitorare il danno polmonare associato al fumo di sigarette elettroniche o all'uso di prodotti da svapo (EVALI). Secondo il CDC, a febbraio 2020 sono stati registrati un totale di 2.807 casi EVALI ospedalizzati o decessi in tutti i 50 stati, nel Distretto di Columbia e in due territori degli Stati Uniti (Porto Rico e Isole Vergini americane). Si prevede che quanto sopra comporterà la crescita del mercato delle lesioni polmonari acute durante il periodo di previsione.

Approfondimenti basati sulla terapia

Basati sulla terapia, il mercato delle lesioni polmonari acute è segmentato in ventilazione meccanica, gestione dei fluidi, farmacoterapia e procedure aggiuntive. Nel 2021, il segmento della ventilazione meccanica rappresentava la quota di mercato maggiore nel mercato globale delle lesioni polmonari acute. La crescita del segmento è attribuita al fatto che la ventilazione meccanica nel danno polmonare acuto (ALI) mira a mantenere l'ossigeno evitando la sua tossicità e le complicazioni associate alla ventilazione.

Mercato delle lesioni polmonari acute, per terapia - 2020 e 2028


Approfondimenti basati sull'utente finale

Basati sull'utente finale, l'analisi acuta Il mercato delle lesioni polmonari è segmentato in ospedali, centri di chirurgia ambulatoriale e altri. Il segmento ospedaliero ha detenuto la quota maggiore del mercato nel 2021 e si prevede che lo stesso segmento registrerà il CAGR più elevato, pari al 4,9% del mercato durante il periodo di previsione.

Approfondimenti strategici

Gli operatori del mercato delle lesioni polmonari acute adottano strategie organiche come il lancio e l'espansione dei prodotti per espandere la propria presenza e il portafoglio di prodotti in tutto il mondo e soddisfare la crescente domanda.

p>

Per terapia

  • Ventilazione meccanica
  • Gestione dei fluidi
  • Farmacoterapia
  • Procedure aggiuntive

Per utente finale

  • Ospedali
  • Centri di chirurgia ambulatoriale
  • Altri

Per area geografica

  • Nord America
    • Stati Uniti
    • Canada
    • Messico
  • Europa
    • Francia
    • Germania
    • Italia
    • Regno Unito
    • Spagna
    • Resto d'Europa
  • Asia Pacifico (APAC)
    • Cina
    • India
    • Corea del Sud
    • Giappone
    • Australia
    • Resto dell'APAC
  • Medio Oriente e Asia Africa (MEA)
    • Sudafrica
    • Arabia Saudita
    • EAU
    • Resto del MEA
  • America centrale e meridionale (SCAM)
    • Brasile
    • Argentina
    • Resto dello SCAM

  • Profili aziendali

    • GlaxoSmithKline plc.
    • Stemedica Cell Technologies, Inc
    • Histocell
    • APEPTICO Forschung und Entwicklung GmbH
    • Windtree Therapeutics, Inc.
    • ReAlta Life Sciences, Inc.
    • Apeiron Biologics AG
    • Qx Therapeutics, Inc.
    • Angion
    • Asklepion Pharmaceuticals, LLC ;                                &n bsp;                       
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which is the potential market for the acute lung injury in terms of region?

Asia Pacific is expected to be the fastest growing region and potential market for acute lung injury. Asia Pacific is expected to expand at a high growth rate. The growth of the acute lung injury market in this region is primarily due to high prevalence of this disease, and the rise in healthcare awareness related to the disease diagnosis. Additionally, developing healthcare infrastructure and increasing investments to boost the manufacturing capacities are projected to drive the Asia Pacific acute lung injury market during the forecast period.

What are the drivers and restraints for the acute lung injury market?

The growth of the market is attributed to increasing prevalence of respiratory diseases, and rising geriatric population drive the market growth. However, high cost of therapies hampers the market growth.

Who are the key players in the acute lung injury market?

The acute lung injury market majorly consists of players like GlaxoSmithKline plc., Stemedica Cell Technologies, Inc, Histocell, APEPTICO Forschung und Entwicklung GmbH, Windtree Therapeutics, Inc., ReAlta Life Sciences, Inc., Apeiron Biologics AG, Qx Therapeutics, Inc., Angion, and Asklepion Pharmaceuticals, LLC. among others. Histocell and APEPTICO Forschung und Entwicklung GmbH are the top most two companies in the market.

The List of Companies - Acute Lung Injury Market

  1. GlaxoSmithKline plc.
  2. Stemedica Cell Technologies, Inc
  3. Histocell
  4. APEPTICO Forschung und Entwicklung GmbH
  5. Windtree Therapeutics, Inc.
  6. ReAlta Life Sciences, Inc.
  7. Apeiron Biologics AG
  8. Qx Therapeutics, Inc.
  9. Angion
  10. Asklepion Pharmaceuticals, LLC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports